13th Dec 2021 21:57
N4 Pharma PLC - Derby, England-based pharmaceutical company - Says preliminary results from mouse immunogenicity studies carried out by Evotec SE using Covid-19 plasmid DNAs and other controls have not shown meaningful immunological response despite good in vitro antigen expression. Lack of immunological response in positive control animals brings into question the validity of the whole study, N4 says. Company says it has strategically decided to focus its resources on advancing its work in gene therapy whilst continuing its vaccine delivery efforts in conjunction with partners working with specific, proprietary products.
"We expect other collaborations will follow, so it makes sense to continue the vaccine platform optimization with collaborators who own their own DNA plasmids and mRNA compounds. This will allow us to focus internal efforts on developing commercial products in the gene therapy space," Chief Executive Nigel Theobald says.
Current stock price: 5.90 pence, down 24% on Monday
Year-to-date change: down 26%
By Arvind Bhunjun; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
N4 Pharma Plc